4.7 Review

Benefits and Harms of Statin Therapy for Persons With Chronic Kidney Disease A Systematic Review and Meta-analysis

期刊

ANNALS OF INTERNAL MEDICINE
卷 157, 期 4, 页码 263-+

出版社

AMER COLL PHYSICIANS
DOI: 10.7326/0003-4819-157-4-201208210-00007

关键词

-

资金

  1. National Institutes of Health
  2. Genzyme

向作者/读者索取更多资源

Background: Statins have uncertain benefits in persons with chronic kidney disease (CKD) because individual trials may have insufficient power to determine whether treatment effects differ with severity of CKD. Purpose: To summarize the benefits and harms of statin therapy for adults with CKD and examine whether effects of statins vary by stage of kidney disease. Data Sources: Cochrane and EMBASE databases (inception to February 2012). Study Selection: Randomized trials comparing the effects of statins with placebo, no treatment, or another statin on mortality and cardiovascular outcomes. Data Extraction: Two independent reviewers extracted data and assessed risk of bias. Data Synthesis: Eighty trials comprising 51 099 participants compared statin with placebo or no treatment. Treatment effects varied with stage of CKD. Moderate-to high-quality evidence indicated that statins reduced all-cause mortality (relative risk [RR], 0.81 [95% CI, 0.74 to 0.88]), cardiovascular mortality (RR, 0.78 [CI, 0.68 to 0.89]), and cardiovascular events (RR, 0.76 [CI, 0.73 to 0.80]) in persons not receiving dialysis. Moderate-to high-quality evidence indicated that statins had little or no effect on all-cause mortality (RR, 0.96 [CI, 0.88 to 1.04]), cardiovascular mortality (RR, 0.94 [CI, 0.82 to 1.07]), or cardiovascular events (RR, 0.95 [CI, 0.87 to 1.03]) in persons receiving dialysis. Effects of statins in kidney transplant recipients were uncertain. Statins had little or no effect on cancer, myalgia, liver function, or withdrawal from treatment, although adverse events were evaluated systematically in fewer than half of the trials. Limitation: There was a reliance on post hoc subgroup data for earlier stages of CKD. Conclusion: Statins decrease mortality and cardiovascular events in persons with early stages of CKD, have little or no effect in persons receiving dialysis, and have uncertain effects in kidney transplant recipients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据